Yesterday, the U.S. Food and Drug Administration (FDA) approved a more flexible design of Hologic Inc.’s (HOLX) MammoSite system, which provides radiation seeds to prevent recurrences of breast cancer. The company intends to launch the radiation therapy system, designed to treat early-stage breast cancer, in the first quarter of fiscal 2010. The MammoSite ML (multi-lumen) radiation therapy system allows physicians to target radiation to areas which are most likely to be affected by cancer and shift the dose away from areas that do not need it. MammoSite devices include balloon catheters that are inserted into the body after the removal of a tumor. A pellet of radioactive material is inside the catheter. The radiation treatment is completed in just five days. The therapy aims to prevent recurrence without affecting healthy tissues. Side effects like skin discoloration, fatigue, etc. are minimized by this therapy. Additionally, the ...

Access Pharmaceuticals, Inc.

(OTC:ACCP)

Many investors have raised concerns with regards to Access Pharmaceuticals being on the OTC. Indeed more than half the time companies which are not listed on a major exchange tend to lie, cheat and do just about anything possible in order to stimulate investor demand. They will reach out to stock promoters, make deals with various PR companies and even go as far as releasing their own false press releases — usually involving buyouts (see OTC:PGYC). Folks, you need not worry, Access Pharma takes part in none of these illegal activities in order to induce demand, rather they focus on a solid and sound business strategy which willslowly take them into the promise land. Patience is a virtue.

MuGard is an interesting product with a lot of potential, and we truly believe that it

...